# Preliminary Cost-Effectiveness of Transcendental Meditation (TM) for Treating PTSD in Veterans

Erik J. Groessl, PhD and Thomas Rutledge, PhD
VA San Diego Healthcare System
University of California San Diego



#### Disclosures

Analysis work was partially paid for by the David Lynch Foundation.

### Background

- The experience of traumatic events often results in intrusive thoughts of the event, difficulty regulating emotions, arousal and sleep problems, and avoidance of cues that remind one of the trauma.
- PTSD is diagnosed when these symptoms do not diminish with time and are functionally impairing.
- PTSD often leads to a range of health problems such as depression, substance use, chronic pain, disability, suicidality, lower QOL, and higher health care costs.
- Rates of PTSD are higher in military veterans, with 22% of combatexposed veterans in recent conflicts meeting criteria for PTSD.

### Background

- Effective treatments for PTSD exist, with trauma-focused, CBT-based therapies such as (PE) and (CPT) recommended as evidence-based in recent PTSD treatment guidelines.
- ► However, trauma-focused therapies for PTSD often have high drop-out rates (~40%) and subsequently, high non-response rates (~ 50%)
- Transcendental Meditation (TM) is a non-trauma-focused treatment that involves the use of a mantra (sound), without concentration or contemplation.
- ► After a series of smaller trials, a DoD-funded trial completed in 2018 randomized 203 veterans with PTSD to either TM, PE, or PTSD health education (HE). (Nidich, 2018).

#### **RCT** Results

- The main result of the RCT was that TM was found to be non-inferior to PE, a first-line guideline-concordant psychotherapy.
- ► The mean decreases in CAPS-IV scores were 16.1, 11.2, and 2.5 for TM, PE, and HE respectively.
- ► Rates of clinically significant improvement (CAPS score decrease ≥ 10) were 61.2%, 41.5% and 32.3% respectively.
- Treatment non-completion rates = 25% TM, 38% PE, and 35% HE.


## Objective

- ► Examine the preliminary cost-effectiveness of TM for military veterans with PTSD based on the recent trial results.
- ▶ Results considered preliminary because...
  - the analysis is based on findings from a single RCT
  - did not track participant health care utilization/ health care costs
  - limited to outcomes measured at three months.

#### Methods

- Markov decision model with repeated cycles to simulate response or non-response to the three study interventions over time from a healthcare organization perspective.
- In the first cycle, each participant (or cohort) accrues an estimated intervention cost
- After the first and subsequent cycles, each participant accrues Quality Adjusted Life Years (QALYs), estimated health care costs associated with intervention response or non-response.

#### Markov Model



## Model Inputs

#### Inputs for the Markov Model were:

- Time Horizon: 5 years (matches previous analyses)
- ► Total Cycles: 20 3-month cycles = 5 years
- Intervention costs various
- Health utility values derived from scientific literature
- Health care costs derived from scientific literature
- Reversion rate 2.5% /3-mo cycle
- Inflation: Costs adjusted to 2023 US\$
- Discount rate: 3% annual (convention for CEA) (Neumann 2017)

#### Intervention Cost Estimates

- ► TM cost \$1,504/participant
  - ► TM administrators in \$2023 plus small add-on for scheduling
- ► PE cost \$2,822/participant
  - ▶ Mavranezouli et al. 2020 CEA of psych treatments for PTSD
  - ► Adjusted for 12 90-minute sessions, \$US, and to \$2023
- ► HE cost \$492/participant
  - ► Groessl et al. 2016 LIFE Study
  - adjusted for # sessions and to \$2023

## Effectiveness and Health Utility Values

- Rates of clinically significant improvement (CAPS score decrease > 10) 61% (TM), 41% (PE), and 32% (HE).
- Health Utility
  - Values range from 0 to 1.0
  - Lack of good estimates
  - Some recent studies have used complex and wide-ranging values (Marseille 2022)
  - ▶ Mavranezouli et al. 2020 conservative values
    - ▶ 0.63 clinically improved
    - ▶ 0.54 not clinically improved

#### Cost Estimates - health care costs

- ► Harper et al. 2022
  - costs for 1,377 VA patients with and without PTSD were tracked
- Adjusting for inflation
  - ▶ \$12,154 annually for with PTSD
  - ▶ \$7,855 annually for without/resolved PTSD


## Sensitivity Analysis

- Model inputs were varied to examine the sensitivity of the results to variation in model inputs.
  - ▶ inputs were varied using 95% confidence intervals when available
  - or + or 20% in either direction
- ► A probabilistic sensitivity analysis (PSA) was conducted
  - Monte Carlo procedure with 5000 simulations
  - inputs values were randomly selected from variable distributions


## Main Results

|                               | HE       | ТМ       | PE       | Difference<br>TM vs HE | Difference<br>TM vs PE | Difference<br>PE vs HE |
|-------------------------------|----------|----------|----------|------------------------|------------------------|------------------------|
| Effectiveness                 |          |          |          |                        |                        |                        |
| -rate of clinical improvement | 0.32     | 0.61     | 0.42     | 0.29                   | 0.19                   | 0.10                   |
| -QALYs                        | 2.60     | 2.70     | 2.63     | 0.10                   | 0.07                   | 0.03                   |
| Costs                         |          |          |          |                        |                        |                        |
| -Intervention costs           | \$492    | \$1,504  | \$2,822  | \$1,012                | -\$1,318               | \$2,330                |
| -Consequent health care costs | \$48,218 | \$43,968 | \$46,753 | -\$4,250               | -\$2,785               | -\$1,465               |
| Total Costs                   | \$48,710 | \$45,472 | \$49,575 | -\$3,238               | -\$4,103               | \$865                  |
| ICER                          |          |          |          | dominant               | dominant               | \$28,833               |
| Incremental NMB               |          |          |          | \$8,267                | \$7,397                | \$870                  |

## Sensitivity Analysis



## ICER Scatterplot



## Summary

- ► TM was the dominant treatment strategy
- TM was more effective clinical improvement in PTSD, results in lower subsequent hc costs, saving money longterm
- Savings per person are means from all participants and thus can be multiplied by a cohort
- ► Limitations include a single RCT, estimates, and 3-month outcomes

#### References

- 1. Nidich S, Mills PJ, Rainforth M, et al. Non-trauma-focused meditation versus exposure therapy in veterans with post-traumatic stress disorder: a randomised controlled trial. Lancet Psychiatry. 2018;5(12):975-986.
- 2. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in Health and Medicine. Second ed. New York, NY: Oxford University Press; 2017.
- 3. Mavranezouli I, Megnin-Viggars O, Grey N, et al. Cost-effectiveness of psychological treatments for post-traumatic stress disorder in adults. PloS one. 2020;15(4):e0232245.
- 4. US Department of Labor. Bureau of Labor Statistics. May 2019 National Occupational Employment and Wage Estimates. https://www.bls.gov/oes/current/oes\_nat.htm#29-0000. Published 2021. Accessed January 28, 2021.
- 5. U.S. Bureau of Labor Statistics. CPI Inflation Calculator. 2023.
- 6. Groessl EJ, Kaplan RM, Castro Sweet CM, et al. Cost-effectiveness of the LIFE Physical Activity Intervention for Older Adults at Increased Risk for Mobility Disability. J Gerontol A Biol Sci Med Sci. 2016.
- 7. Harper KL, Moshier S, Ellickson-Larew S, et al. A prospective examination of health care costs associated with posttraumatic stress disorder diagnostic status and symptom severity among veterans. Journal of traumatic stress. 2022;35(2):671-681.
- 8. Neria Y, al. e. Transcendental Meditation in Veterans and First Responders With PTSD. (Trial registration). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05645042. Published 2022. Accessed 2023.